H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $35 from $29 and keeps a Buy rating on the shares following FDA approval of Yutrepia for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. For those transitioning from nebulized formulations, the firm believes Yutrepia could emerge as the prostacyclin of first choice. Yutrepia’s “distinct” formulation and clinical advantages reinforce its potential to become the preferred inhaled option and a meaningful driver of market expansion, contends H.C. Wainwright.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Buy Rating for Liquidia Technologies Driven by FDA Approval and Strategic Launch of Yutrepia
- Liquidia price target raised to $23 from $20 at Wells Fargo
- Strategic Launch and Market Potential of Yutrepia Justifies Buy Rating for Liquidia Technologies
- Liquidia price target raised to $37 from $29 at BTIG
- Liquidia price target raised to $31 from $27 at Jefferies